Evidence map›Paper›PMID 25602014›Full record

ArticlePhysiological reports2015

Low glucose microenvironment of normal kidney cells stabilizes a subset of messengers involved in angiogenesis.

Elodie de Laplanche, Asma Boudria, Estelle Dacheux, Anne Vincent, Nicolas Gadot, Fouzia Assade, Katy Le Corf, Xavier Leroy, Florence Mège Lechevallier, Béatrice Eymin and 2 more

Open access · goldAbstract read
In one paragraph

Article in Physiological reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Elodie de LaplancheUniversité de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France.
Asma BoudriaInstitut Albert Bonniot Equipe 2 Bases Moléculaires de la Progression des Cancers du Poumon, INSERM U823/Université Joseph Fourier, Grenoble, F-38000, France.
Estelle DacheuxUniversité de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France.
Anne VincentUniversité de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France.
Nicolas GadotUniversité de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Department of Pathology, Hôpital Edouard Herriot, Lyon, F-69000, France.
Fouzia AssadeUniversité de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France.
Katy Le CorfUniversité de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France.
Xavier LeroyInstitut de Pathologie, CHRU, Faculté de Médecine, Université de Lille, Lille, F-59000, France.
Florence Mège LechevallierDepartment of Pathology, Hôpital Edouard Herriot, Lyon, F-69000, France.
Béatrice EyminInstitut Albert Bonniot Equipe 2 Bases Moléculaires de la Progression des Cancers du Poumon, INSERM U823/Université Joseph Fourier, Grenoble, F-38000, France.
Nicole Dalla VeneziaUniversité de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France.
Hélène SimonnetUniversité de Lyon, Lyon, F-69000, France Université Lyon 1, Lyon, F-69000, France Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, F-69000, France.
Université Claude Bernard Lyon 1 · FRInserm · FRHôpital Edouard Herriot · FRUniversité de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As glucose is a mandatory nutrient for cell proliferation and renewal, it is suspected that glucose microenvironment is sensed by all cell types to regulate angiogenesis. Several glucose-sensing components have been partially described to respond to high glucose levels. However, little is known about the response to low glucose. Here, we used well-differentiated isolated normal rat renal tubules under normal oxygenation conditions to assess the angiogenic response to low glucose. In apparent paradox, but confirming observations made separately in other models, high glucose but also low glucose increased mRNA level of vascular endothelial growth factor A (VEGFA). A subset of mRNAs including hypoxia-inducible factor 1A (HIF1A), angiopoietin receptor (TIE-2), and VEGF receptor 2 (FLK1) were similarly glucose-sensitive and responded to low glucose by increased stability independently of HIF1A and HIF2A proteins. These results contribute to gain some insights as to how normal cells response to low glucose may play a role in the tumor microenvironment.

Indexed as

Glucose sensingHIF1Ametabolismnormal renal tubuleVEGFA

Identifiers

PMID25602014
PMCPMC4387757
OpenAlexW2121642100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.